TFX logo

Teleflex Incorporated (TFX)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Teleflex Incorporated (TFX) with AI Score 48/100 (Weak). Teleflex Incorporated is a global provider of single-use medical devices used in critical care and surgical procedures. Market cap: $0, Sector: Healthcare.

Last analyzed: Feb 5, 2026
Teleflex Incorporated is a global provider of single-use medical devices used in critical care and surgical procedures. The company's diverse product portfolio and global reach position it as a key player in the medical device industry.
48/100 AI Score

Teleflex Incorporated (TFX) Healthcare & Pipeline Overview

CEOStuart A. Randle
Employees14100
HeadquartersWayne, PA, US
IPO Year1980

Teleflex Incorporated (TFX) is a leading medical device company providing critical care and surgical solutions globally, driven by innovative single-use products and a strong market presence, offering investors a stable dividend yield and potential for long-term growth in a resilient healthcare sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 5, 2026

Investment Thesis

Teleflex Incorporated presents a notable research candidate due to its established position in the growing medical device market and its focus on single-use products, which benefit from recurring demand. With a current dividend yield of 1.28%, TFX offers a steady income stream. The company's diverse product portfolio and global reach mitigate risk and provide multiple avenues for growth. Key value drivers include the increasing adoption of minimally invasive procedures and the aging global population, which drives demand for Teleflex's urology and vascular access products. While the company's negative P/E ratio of -14.28 and negative profit margin of -10.3% raise concerns, strategic initiatives to improve operational efficiency and product innovation could drive future profitability. Investors should monitor the company's progress in these areas to assess the long-term potential.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market Cap of $4.68B reflects Teleflex's significant presence in the medical device industry.
  • Gross Margin of 53.7% indicates strong pricing power and efficient manufacturing processes.
  • Dividend Yield of 1.28% provides a steady income stream for investors.
  • Beta of 0.91 suggests lower volatility compared to the overall market.
  • Global reach with products used in critical care and surgical applications worldwide.

Competitors & Peers

Strengths

  • Diverse product portfolio.
  • Global presence and distribution network.
  • Established brand reputation.
  • Focus on single-use devices.

Weaknesses

  • Negative profit margin.
  • High debt levels.
  • Dependence on key products.
  • Exposure to regulatory risks.

Catalysts

  • Ongoing: Increasing adoption of minimally invasive procedures.
  • Ongoing: Aging global population driving demand for urology and vascular access products.
  • Upcoming: Potential regulatory approvals for new products.
  • Ongoing: Expansion into new geographic markets.

Risks

  • Potential: Product recalls or safety concerns.
  • Ongoing: Intense competition from other medical device manufacturers.
  • Potential: Changes in healthcare regulations or reimbursement policies.
  • Ongoing: Economic downturns impacting healthcare spending.
  • Potential: Fluctuations in foreign exchange rates.

Growth Opportunities

  • Expansion of the UroLift System: The UroLift System, a minimally invasive treatment for benign prostatic hyperplasia (BPH), represents a significant growth opportunity. The global BPH market is projected to reach billions of dollars, driven by an aging population and increasing awareness of minimally invasive treatment options. Teleflex can capitalize on this trend by expanding its sales and marketing efforts and securing favorable reimbursement policies.
  • Penetration of Emerging Markets: Emerging markets, such as China and India, offer substantial growth potential for Teleflex. These markets are experiencing rapid growth in healthcare spending and increasing demand for advanced medical technologies. Teleflex can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets and capture a larger share of the global medical device market.
  • Product Innovation and Development: Continuous innovation is crucial for maintaining a competitive edge in the medical device industry. Teleflex can invest in research and development to develop new and improved products that address unmet clinical needs. This includes expanding its portfolio of single-use devices and developing innovative solutions for minimally invasive surgery and critical care.
  • Strategic Acquisitions: Teleflex can pursue strategic acquisitions to expand its product portfolio, enter new therapeutic areas, and gain access to new technologies. Acquisitions can also provide synergies and cost savings, enhancing the company's overall profitability. Potential targets include companies with complementary product lines or innovative technologies in the medical device space.
  • Increased Focus on Home Healthcare: The shift towards home healthcare is creating new opportunities for medical device companies. Teleflex can develop and market products that are suitable for home use, such as remote patient monitoring devices and home infusion systems. This can help to reduce healthcare costs and improve patient outcomes.

Opportunities

  • Expansion in emerging markets.
  • New product development and innovation.
  • Strategic acquisitions.
  • Growth in home healthcare market.

Threats

  • Intense competition.
  • Pricing pressures.
  • Product liability claims.
  • Economic downturns.

Competitive Advantages

  • Established brand reputation (Arrow, UroLift).
  • Proprietary technologies and intellectual property.
  • Extensive distribution network.
  • High switching costs for customers due to regulatory requirements and clinical preferences.

About TFX

Teleflex Incorporated, founded in 1943 and headquartered in Wayne, Pennsylvania, has evolved into a prominent global provider of single-use medical devices. The company focuses on designing, developing, manufacturing, and supplying a broad range of products for common diagnostic and therapeutic procedures, primarily in critical care and surgical applications. Teleflex's portfolio includes vascular access products under the Arrow brand, featuring catheters, navigation systems, and intraosseous access systems. These products facilitate intravenous therapies, blood pressure measurement, and blood sampling. The company also offers interventional products, such as coronary catheters, structural heart therapies, and peripheral intervention devices, utilized by interventional cardiologists, radiologists, and vascular surgeons. Furthermore, Teleflex provides anesthesia products, including airway and pain management solutions, and surgical products like ligation clips and fascial closure systems. A key offering is the UroLift System, an innovative solution for treating lower urinary tract symptoms related to benign prostatic hyperplasia. Teleflex serves a diverse customer base, including hospitals, healthcare providers, medical device manufacturers, and home care markets, solidifying its position as a comprehensive solutions provider in the medical device industry.

What They Do

  • Designs, develops, and manufactures single-use medical devices.
  • Supplies products for diagnostic and therapeutic procedures.
  • Offers vascular access products, including catheters and navigation systems.
  • Provides interventional products for cardiology and radiology.
  • Offers anesthesia and surgical products.
  • Markets the UroLift System for treating BPH.
  • Provides respiratory products for oxygen and ventilation management.
  • Offers urology products, including catheters and accessories.

Business Model

  • Develops and manufactures medical devices.
  • Sells products to hospitals, healthcare providers, and medical device manufacturers.
  • Generates revenue through product sales and related services.
  • Focuses on single-use devices to ensure recurring revenue.

Industry Context

Teleflex operates in the medical device industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and advancements in medical technology. The market for single-use medical devices is expanding due to the growing emphasis on infection control and patient safety. Teleflex competes with other medical device manufacturers, including ALKS, ARWR, BLCO, CRSP and KRYS, focusing on specific therapeutic areas. The industry is subject to stringent regulatory requirements and pricing pressures, requiring companies to invest in research and development and maintain efficient operations to remain competitive.

Key Customers

  • Hospitals
  • Healthcare providers
  • Medical device manufacturers
  • Home care markets
AI Confidence: 70% Updated: Feb 5, 2026

Financials

Chart & Info

Teleflex Incorporated (TFX) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TFX.

Price Targets

Wall Street price target analysis for TFX.

MoonshotScore

48/100

What does this score mean?

The MoonshotScore rates TFX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Classification

Sector Healthcare Industry Medical - Instruments & Supplies

Competitors & Peers

Latest News

Latest Teleflex Incorporated Analysis

TFX Healthcare Stock FAQ

What does Teleflex Incorporated do?

Teleflex Incorporated is a global medical device company that designs, develops, manufactures, and supplies a wide range of single-use medical devices. These devices are used in various diagnostic and therapeutic procedures, primarily in critical care and surgical settings. The company's product portfolio includes vascular access devices, interventional cardiology products, anesthesia and surgical products, urology products, and respiratory products. Teleflex serves hospitals, healthcare providers, medical device manufacturers, and home care markets worldwide, focusing on providing innovative solutions that improve patient outcomes and enhance healthcare efficiency.

Is TFX stock worth researching?

TFX stock presents a mixed investment picture. While the company has a strong market position and a diverse product portfolio, its negative P/E ratio and profit margin raise concerns. The dividend yield of 1.28% provides some downside protection. Investors may want to evaluate the company's growth opportunities, such as the expansion of the UroLift System and penetration of emerging markets, as well as the potential risks, such as intense competition and regulatory changes. A thorough analysis of the company's financial performance and strategic initiatives is crucial before making an investment decision.

What are the main risks for TFX?

Teleflex faces several key risks. Intense competition in the medical device industry could pressure pricing and market share. Changes in healthcare regulations or reimbursement policies could negatively impact revenue. Product recalls or safety concerns could damage the company's reputation and lead to liability claims. Economic downturns could reduce healthcare spending and demand for Teleflex's products. Fluctuations in foreign exchange rates could affect the company's international sales and profitability. Effective risk management and mitigation strategies are essential for Teleflex to navigate these challenges.

What are the key factors to evaluate for TFX?

Teleflex Incorporated (TFX) currently holds an AI score of 48/100, indicating low score. Key strength: Diverse product portfolio.. Primary risk to monitor: Potential: Product recalls or safety concerns.. This is not financial advice.

How frequently does TFX data refresh on this page?

TFX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven TFX's recent stock price performance?

Recent price movement in Teleflex Incorporated (TFX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider TFX overvalued or undervalued right now?

Determining whether Teleflex Incorporated (TFX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying TFX?

Before investing in Teleflex Incorporated (TFX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Stock data pending update.
  • Financial data based on available information and may be subject to change.
Data Sources

Popular Stocks